A capsule touched down in the Utah desert last February, kicking up dust and carrying something unusual: crystals of ritonavir, a common HIV drug, but grown in a way no factory on Earth can replicate. Varda Space Industries' W-1 capsule wasn't just delivering pharmaceutical experiments. It was proving a point about the emerging challenge of reentry logistics.
Getting things up to orbit? That's practically routine now. Getting them back? That's the bottleneck.
The first commercial stand-alone manufacturing capsule to return from orbit, W-1 also secured the first FAA Part 450 reentry license for an in-space manufacturing mission—a regulatory precedent that matters more than it might sound. Because while analysts keep predicting a global space economy barreling toward $1.8 trillion by 2035 (McKinsey and the World Economic Forum refreshed that figure in April 2026), a curious constraint has emerged for the small but ambitious in-space manufacturing sector: not launch cadence, not microgravity physics, but logistics.
Making things in weightlessness works. Returning them reliably, repeatedly, and without burning through budgets is proving harder than anyone expected. The in-space manufacturing market shows significant growth projections across vendor studies, though methodologies vary widely. Whether that materializes depends almost entirely on solving the reentry problem.
A Small Sector, Big Ambitions
The in-space manufacturing industry remains niche—22 funding rounds totaling around $397 million through early 2026, according to Tracxn. But 2025 saw a sharp influx: roughly $227 million, driven almost entirely by Varda's $187 million Series C announced last July.
That's not an industry. Not yet. It's a handful of well-capitalized bets.
Varda has been the most aggressive. After W-1's landing at Utah Test and Training Range in February 2024, the company put W-2 and W-3 down at Australia's Koonibba Test Range just ten weeks apart—February and May of last year. W-6, launched aboard SpaceX's Transporter-16 in late March, reentered successfully in mid-May, validating autonomous navigation and an ablative carbon-phenolic heat shield while hauling hypersonic data payloads for Prometheus and the Air Force Research Laboratory. The company has lined up a 20-reentry agreement with Southern Launch running through 2028, a signal it plans to keep the cadence high.
Then there's Space Forge, the UK startup taking a different technical path. It launched ForgeStar-1 last June and by year's end had achieved on-orbit plasma generation—critical for semiconductor processing in microgravity, the company says. In October, Space Forge tested its Pridwen deployable heat shield during zero-gravity flights. This past June, it secured around €10 million in new ESA funding to push Pridwen toward commercial readiness.
Unlike Varda's ablative shields, which are consumed with each reentry and must be replaced, Pridwen is designed to be recovered and refurbished. Space Forge is betting that reusability economics will beat per-flight replacement costs. Whether that gamble pays off depends on a test the company hasn't run yet: an actual orbital reentry. That's likely 12 to 24 months out, assuming funding and development milestones hold.
Why Now? Three Converging Pressures
Three forces are pushing reentry logistics from niche engineering challenge to critical infrastructure layer.
First: the science is moving past proof-of-concept. NASA reported in January 2025 that Flawless Photonics had produced more than 11.9 kilometers of ZBLAN optical fiber aboard the International Space Station during a manufacturing run spanning mid-February to mid-March 2024. Quality metrics haven't been published widely, but the sheer volume hints at operational feasibility. Varda's W-1 successfully crystallized metastable Form III ritonavir—a pharmaceutical polymorph terrestrial processes struggle to produce—and brought it back intact through reentry. And in mid-May of last year, Varda announced a collaboration with United Therapeutics to develop microgravity-enabled formulations for rare pulmonary diseases. It was the sector's first explicit therapeutic development partnership, a shift from pure research toward something that might, eventually, reach patients.
Second: launch is no longer the gatekeeper. SpaceX flew roughly half of all global launches in 2025, per BryceTech's April year-in-review. Rideshare missions like Transporter have turned small-payload access to orbit into something closer to a commodity. The return trip? Not so much. SpaceX's Cargo Dragon can haul about 3,000 kilograms of pressurized cargo down from the ISS, but it serves NASA's schedule and research queue first. For companies trying to iterate quickly on materials processing—testing batches of drug crystals, semiconductor wafers, optical components—waiting months for a Dragon slot kills momentum. Development cycles slow. Capital burns.
Third: regulatory frameworks are solidifying, if slowly. The FAA's Part 450 streamlined licensing process, battle-tested first by Varda, is setting precedent. By early 2024, SpaceNews noted the FAA was trending toward requiring reentry licenses before launch, cutting downstream program risk. Varda's expansion to Koonibba showed that non-U.S. reentry sites can work within international coordination frameworks; Australia published airspace guidance for reentry corridors in December 2024. The regulatory fog is lifting, at least a little.
Who's Racing Whom?
The competitive landscape reveals sharply different technical philosophies—and different market bets.
Varda has the most flight heritage. Six missions as of mid-2026, with plans to scale "multiple W-series flights" this year, according to Ars Technica's coverage of the United Therapeutics partnership. The company's ablative C-PICA heat shield is consumable—each reentry chews it up—but the approach has proven robust. Varda is chasing three revenue streams, per cofounder Delian Asparouhov's remarks last July: military hypersonics testing, pharmaceutical R&D, and general microgravity research.
The United Therapeutics collaboration signals a pivot from pure R&D toward formulation development. But there's a high wall ahead: FDA current good manufacturing practice (cGMP) validation. Proving a crystal structure is interesting in a lab is one thing. Proving it can be manufactured reproducibly, at scale, under regulatory scrutiny? That's another.
Space Forge is betting semiconductors and refurbishability will pay off. CEO Joshua Western described the December plasma demonstration as proof of a "new manufacturing frontier." The company partnered with Intuitive Machines last October to advance U.S.-based semiconductor manufacturing and reentry tech integration. ForgeStar-1 is still in orbit. The Pridwen heat shield has been tested in parabolic flights but hasn't faced the plasma furnace of reentry yet. That first materials return—when it comes—will validate whether the deployable shield architecture delivers on its economic promise, or whether Space Forge's bet was premature.
Dispatch, a Y Combinator-backed startup founded by Payton Case and Andrew Mello (both alumni of Astranis and other aerospace ventures), emerged from stealth earlier this year. The company's Free Flyer 1 system targets missions up to 180 days with a maximum payload of 30 kilograms and promises payload recovery within six hours of landing. According to the company's pre-release payload user guide, the capsule uses replaceable heat shields and interfaces designed for high-cadence operations. Dispatch raised an initial $500,000 in early 2026 and is eyeing a subscale reentry demo in 2027. The pitch is blunt: modular, refurbishable reentry as a service. No frills.
Reditus and Inversion Space round out the U.S. cohort. Reditus announced its ENOS Mk1 demo for summer last year in a November 2025 statement, positioning a reusable capsule for payloads hosted roughly eight weeks in orbit. Inversion secured an FAA Part 450 reentry license for its Ray demonstrator back in October 2024, though the company's primary focus is rapid cargo delivery rather than sustained manufacturing runs.
Internationally, ESA's Space Rider is advancing reusable uncrewed reentry, with thermal protection milestones completed in the spring, though the first flight remains subject to the usual program schedule uncertainties. Sierra Space's Dream Chaser, originally contracted for ISS cargo resupply under NASA's CRS-2, was modified in September 2025 to pursue a free-flying demo after NASA adjusted the contract. Dream Chaser's runway-landing capability offers gentler cargo handling—critical for delicate payloads—but at significantly higher development cost and complexity. Whether that trade-off pencils out remains unclear.
The Next 18 Months Will Tell
For pharmaceuticals, the pathway is clearest but still steep. Varda and United Therapeutics will need to thread FDA requirements that demand not just improved crystal properties but reproducible, scalable manufacturing under cGMP standards. Near-term value lies in R&D acceleration—testing formulations terrestrial methods can't touch—but revenue-scale production requires clinical validation and regulatory approvals measured in years, not quarters. Patience will be tested.
Semiconductors face different gates. Space Forge's plasma demonstration was a tool pathfinding exercise; the real test is whether microgravity-processed wafers deliver measurable performance gains that justify the cost premium. An npj Microgravity meta-analysis published in April 2025 cataloged more than 160 microgravity semiconductor crystal growth experiments, reporting various property improvements. But peer-reviewed, independently verified performance data on commercially relevant materials? Sparse. Buyers—AI data centers, quantum computing labs, power electronics manufacturers—will demand hard numbers on yield, defect density, and electrical characteristics before they write checks.
Photonics may be furthest along in volume production proof. The 11.9-kilometer ZBLAN run demonstrated manufacturing at scale, though attenuation figures and commercial quality benchmarks remain closely held. If those metrics meet or exceed terrestrial fiber specs, orbital production could find early commercial traction in specialty applications like undersea cables or defense communications. A niche, but a real one.
Economics hinge on cadence and cost. Varda's 20-reentry agreement with Koonibba signals confidence in sustained ops. Space Forge's ESA funding backstops Pridwen development. Dispatch's emphasis on six-hour payload turnaround addresses a genuine customer pain point: researchers and manufacturers want their samples back fast to close iteration loops. Speed matters as much as cost, maybe more in the early days.
Perhaps the most telling signal comes from infrastructure bets. Starlab, the Voyager Space and Airbus joint venture, completed NASA's Commercial Critical Design Review in February and announced payload reservations including United Semiconductors in March. As commercial stations come online later this decade and the ISS approaches its 2030 retirement, demand for dedicated reentry vehicles—beyond Dragon's constrained capacity—will grow sharply.
The companies that crack refurbishability, regulatory compliance, and rapid turnaround at scale won't just be vendors. They'll own the logistics backbone of a new industrial frontier.
The race, it turns out, isn't to make things in space anymore.
It's to bring them home.
